Immunome (IMNM) Stock Statistics & Valuation Metrics

Immunome has a market cap or net worth of $2.42B. The enterprise value is $1.19B.

Immunome has 113,133,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunome’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -33.55%.

The current PE Ratio of Immunome is ―. Immunome’s PEG ratio is 0.17.

In the last 12 months, Immunome had revenue of 6.94M and earned -212.39M in profits. Earnings per share was -2.43.

In the last 12 months, operating cash flow was -190.92M and capital expenditures -9.69M, giving a free cash flow of -200.60M billion.

Immunome pays an annual dividend of ―, resulting in a dividend yield of ―

Immunome upcoming earnings date is May 7, 2026, After Close (Confirmed).

Immunome as a current ratio of 14.69, with Debt / Equity ratio of 0.61%

In the past 12 months, Immunome has paid 0.00 in taxes.

Immunome EV to EBITDA ratio is -5.81, with an EV/FCF ratio of -6.11.

Immunome has $653.48M in cash and marketable securities with $3.85M in debt, giving a net cash position of $649.63M billion.

Gross margin is -630.28%, with operating margin of -3084.76%, and net profit margin of -3059.99%.

The average price target for Immunome is $35.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy